{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

CONTROL STUDY

(Kindly fill in the relevant information or tick, as appropriate.)

Doctor’s details:
@if(isset(session()->get('doctor')['vCentralCode']))
@else
@endif
Years of clinical practice: *

Predominant type of practice: *

Lipid management in primary prevention setting
  1. How many patients of dyslipidemia do you see every day in your practice? *

  2. Which of the following are risk factors that might prompt you to screen for dyslipidaemia? *

  3. When do you recommend a Lipid profile to your patients? *

  4. What is the frequency of lipid profile testing recommended by you in your clinical practice? *

  5. Do you set LDL-C targets for each of your patients? *

  6. What are the approaches followed by you to choose the intensity of statin therapy? *

  7. At what lipid levels do you initiate lipid lowering therapy in patients with the following risk factors?*
    8. Risk Factors LDL-C levels (mg/dl)
    >200 150-199 100-149 ≤100
    Age ≥ 45
    BMI ≥ 25kg/m2
    Hypertension
    Dyslipidaemia
    CAD
    Family history of ASCVD in a first-degree relative
    Smoking
  8. Kindly mark your therapeutic preference in specific dyslipidaemia Profiles *

    9. In your practice what is your preference of using lipid lowering agent in primary prevention for following patient profile. (Please rank from 1 -4 with 1 being most and 4 as least)


    a. Type 2 diabetes with atherogenic dyslipidaemia (LDL > 160 mg/dl, TG-200-499 mg/dl, HDL< 40 mg/dl without CHD or CHD risk equivalents)

    Lipid Lowering agents Rank 1 Rank 2 Rank 3 Rank 4

    b. Moderate Hypertriglyceridemia (TG-200-499 mg/DL and LDL at goal)

    Lipid Lowering agents Rank 1 Rank 2 Rank 3 Rank 4

    c. Patients with borderline high LDL level (LDL- 130-160 mg/dl, normal TG < 200 mg/dl, without CHD or CHD risk equivalents)

    Lipid Lowering agents Rank 1 Rank 2 Rank 3 Rank 4

    d. Young patients with LDL level between 160 to 200 mg/dl, normal TG < 200 mg/dl, with CHD risk equivalents like smoking and obesity)

    Lipid Lowering agents Rank 1 Rank 2 Rank 3 Rank 4
  9. What percentage of your patients on statins reach target goals of LDL *

  10. Which strategy would you prefer in patients on statin and not at LDL-C goals? *

  11. What percentage of patients do not tolerate statin in your practice? *

  12. Which are the most commonly observed adverse events with statin use in your practice? *

  13. What are your preferred approaches for management of statin intolerance? *

  14. Which of the following agents most commonly found to cause myalgia? *

  15. In your regular practice, how significant is it to consider renal function in the overall clinical outcome of your patient with ASCVD risk or established ASCVD? *

  16. In primary prevention for persons over age 40 with CKD but not on dialysis, do you prefer to initiate statin / statin + ezetimibe? *

  17. What % of patients are non-compliant to statins? *

  18. With positive results from “Evaluation of Major Cardiovascular events in patients with or at high risk for cardiovascular disease who are statin intolerant treated with Bempedoic Acid or Placebo” (CLEAR Outcome) – would you be keen on adding Bempedoic acid to statin therapy for more patients ? *

  19. In elderly CKD patient with diabetes, which of the following will be your statin of choice with strength? *

  20. In your practice in adult patients with diabetes and proteinuria, and taking a stable dose of RAAS inhibitors, which of the following statin do you prefer? *

  21. In which of the following factors do you take into consideration while choosing the combination of Aspirin with statin? *
    (choose more than 1 if applicable)